C L X INVESTMENT COMPANY INC - 500 Beiträge pro Seite
eröffnet am 04.09.07 11:18:33 von
neuester Beitrag 19.09.08 08:18:56 von
neuester Beitrag 19.09.08 08:18:56 von
Beiträge: 43
ID: 1.132.448
ID: 1.132.448
Aufrufe heute: 0
Gesamt: 11.421
Gesamt: 11.421
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 9831 | |
| vor 47 Minuten | 5813 | |
| vor 54 Minuten | 5220 | |
| vor 1 Stunde | 3123 | |
| heute 17:14 | 2970 | |
| vor 56 Minuten | 2742 | |
| vor 1 Stunde | 2183 | |
| 08.05.24, 11:56 | 2074 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 2. | 18.722,39 | -0,28 | 151 | |||
| 2. | 8. | 10,000 | -3,29 | 90 | |||
| 3. | 3. | 159,42 | +1,89 | 74 | |||
| 4. | 1. | 0,2030 | -6,45 | 68 | |||
| 5. | 26. | 4,5630 | +68,63 | 52 | |||
| 6. | 18. | 11,992 | +45,23 | 45 | |||
| 7. | 9. | 28,29 | +74,54 | 39 | |||
| 8. | 11. | 6,9420 | +2,09 | 38 |
Feedback
Moin, moin Leute
Durch den DD bei AVWI bin ich auf CLXN (A0JDEH) gestossen. Es gibt Zusammenhänge zwischen beiden Firmen. Die Kursentwicklung von CLXN lässt aber darauf schließen, dass hier etwas im Busch ist, das eventuell unabhängig von den AVWI-News (Merger) ist. Ich bin aber noch am recherchieren und pack mir das Ding auf die WL!
Wie seht ihr das?!?
Rochester NY, Aug 31, 2007 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com names (OTCBB: CLXN) CLX Investment Company Inc. It's "Bulls on Parade"! To feature your publicly traded company in our alerts, email us at info@otc-advisors.com.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 41% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
Most Recent News:
August 31, 2007 - CLX Investment Company, Inc. today alerted shareholders that ActionView International, in which CLX owns over 6 million shares of common stock, has announced an agreement to become the public vehicle for the entrance of Dalian Chuming Group Co., LTD, a major pork producer in China, into the U.S. markets.
Dalian Chuming Group Co., LTD is a private Chinese company that is seeking a listing in the U.S. public markets through a reverse merger transaction. The preliminary agreement under which ActionView International would serve as the public company for Dalian Chuming Group calls for a period of additional due diligence followed by a definitive agreement between Dalian Chuming Group and ActionView International.
Dalian Chuming Group Co., LTD (www.chuminggroup.com) is a major producer and exporter of fresh and frozen pork and other cooked meat products. The Chuming Group is among a select group of industrialized farming corporations in northeastern China and is known for its international quality management standards and international safety certifications. In late 2006, the company officially opened a $2.9 million feedmill with a capacity of 200,000 tons per year that will support its expansion of pork production. The pursuit of a U.S. public listing is expected to allow the Chuming Group to expand into additional worldwide markets.
"Given CLX's stock ownership position in ActionView International, we wanted to alert our shareholders of the agreement for ActionView to become the public vehicle for the Dalian Chuming Group reverse merger transaction," stated Steven R. Peacock, consultant CEO of CLX Investment Company. "Clearly, this transaction has the potential to deliver long-term value for CLX shareholders through the company's common stock position in ActionView, especially with the completion of the reverse merger and a future valuation of the company based on the revenues and assets of Dalian Chuming Group." In July 2005, CLX made a drawdown line of credit available to ActionView International. As a result of providing this capital, CLX was issued shares of ActionView International common stock.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
Durch den DD bei AVWI bin ich auf CLXN (A0JDEH) gestossen. Es gibt Zusammenhänge zwischen beiden Firmen. Die Kursentwicklung von CLXN lässt aber darauf schließen, dass hier etwas im Busch ist, das eventuell unabhängig von den AVWI-News (Merger) ist. Ich bin aber noch am recherchieren und pack mir das Ding auf die WL!
Wie seht ihr das?!?
Rochester NY, Aug 31, 2007 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com names (OTCBB: CLXN) CLX Investment Company Inc. It's "Bulls on Parade"! To feature your publicly traded company in our alerts, email us at info@otc-advisors.com.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 41% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
Most Recent News:
August 31, 2007 - CLX Investment Company, Inc. today alerted shareholders that ActionView International, in which CLX owns over 6 million shares of common stock, has announced an agreement to become the public vehicle for the entrance of Dalian Chuming Group Co., LTD, a major pork producer in China, into the U.S. markets.
Dalian Chuming Group Co., LTD is a private Chinese company that is seeking a listing in the U.S. public markets through a reverse merger transaction. The preliminary agreement under which ActionView International would serve as the public company for Dalian Chuming Group calls for a period of additional due diligence followed by a definitive agreement between Dalian Chuming Group and ActionView International.
Dalian Chuming Group Co., LTD (www.chuminggroup.com) is a major producer and exporter of fresh and frozen pork and other cooked meat products. The Chuming Group is among a select group of industrialized farming corporations in northeastern China and is known for its international quality management standards and international safety certifications. In late 2006, the company officially opened a $2.9 million feedmill with a capacity of 200,000 tons per year that will support its expansion of pork production. The pursuit of a U.S. public listing is expected to allow the Chuming Group to expand into additional worldwide markets.
"Given CLX's stock ownership position in ActionView International, we wanted to alert our shareholders of the agreement for ActionView to become the public vehicle for the Dalian Chuming Group reverse merger transaction," stated Steven R. Peacock, consultant CEO of CLX Investment Company. "Clearly, this transaction has the potential to deliver long-term value for CLX shareholders through the company's common stock position in ActionView, especially with the completion of the reverse merger and a future valuation of the company based on the revenues and assets of Dalian Chuming Group." In July 2005, CLX made a drawdown line of credit available to ActionView International. As a result of providing this capital, CLX was issued shares of ActionView International common stock.
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
ich beobachte die auch seit freitag, hab mich aber lieber auch avwi, ivgr und erfw konzentriert. man kann ja nicht überall dabei sein.
Lese erst mal den schwedischen Bericht über HandiLab, bevor Du hier einsteigst! Suche über Google!
Ich kann's auch kurz machen: Die Zuverlässigkeit dieser Tests wird bezweifelt und von der Benutzung abgeraten.
Über die Konkurrenzprodukte kann man übrigens das gleiche lesen.
Wie soll man damit auf dem Markt denn Erfolg haben? Außerdem werden die Produkte nur über sehr wenige Internethändler feilgeboten.
Ob CLXN von AVWI profitiert, ist die große Frage. Ich tippe, nein! Ich tippe eher, angeblich hatte man sich kurz vorher von den Aktien mit Verlust getrennt und das Geschäft machen die Bickels dann privat, so ist es ja auch mit 3 Deals bei SIVC gelaufen. Mache Dir keine falschen Hoffnungen!
Zum Traden ist diese Aktie natürlich geeignet!
Ich spekuliere mal:
Erst ist TLTK gelaufen und ich schätze Javelin bzw. Bickel waren nicht involviert und haben sich dann gedacht, das könnte man auch für sich nutzen.
Du hast den Betrug ja doch wohl bei AVWI gesehen! Der eine spricht von Merger und der andere von Reverse Merger. Das sind zwei völlig verschiedene paar Schuhe und wenn behauptet wird, da gäbe es einen vorläufigen Vertrag, dann verstehe ich nicht, warum man sich dann nicht einig ist! Die lassen ganz offen den Betrug durchblicken und die dummen Amis kaufen trotzdem zu Höchstpreisen, weil sie die News nicht gegenprüfen!
Ich kann's auch kurz machen: Die Zuverlässigkeit dieser Tests wird bezweifelt und von der Benutzung abgeraten.
Über die Konkurrenzprodukte kann man übrigens das gleiche lesen.
Wie soll man damit auf dem Markt denn Erfolg haben? Außerdem werden die Produkte nur über sehr wenige Internethändler feilgeboten.
Ob CLXN von AVWI profitiert, ist die große Frage. Ich tippe, nein! Ich tippe eher, angeblich hatte man sich kurz vorher von den Aktien mit Verlust getrennt und das Geschäft machen die Bickels dann privat, so ist es ja auch mit 3 Deals bei SIVC gelaufen. Mache Dir keine falschen Hoffnungen!
Zum Traden ist diese Aktie natürlich geeignet!
Ich spekuliere mal:
Erst ist TLTK gelaufen und ich schätze Javelin bzw. Bickel waren nicht involviert und haben sich dann gedacht, das könnte man auch für sich nutzen.
Du hast den Betrug ja doch wohl bei AVWI gesehen! Der eine spricht von Merger und der andere von Reverse Merger. Das sind zwei völlig verschiedene paar Schuhe und wenn behauptet wird, da gäbe es einen vorläufigen Vertrag, dann verstehe ich nicht, warum man sich dann nicht einig ist! Die lassen ganz offen den Betrug durchblicken und die dummen Amis kaufen trotzdem zu Höchstpreisen, weil sie die News nicht gegenprüfen!
Wenn Du nicht gerade traden willst, dann lasse die Finger von
AVWI, CLXN, FCCN, HYRF, GRXI, UCOI und YHGG! Das sind die Klienten der Javelin Holding, vormals Nicholas Holding und die Vorstände sind auch teils die gleichen. Über deren Betrügereien gibt es gar bei Amazon ein Buch - leider geht das nur bis zur Fusion mit YaSheng!
AVWI, CLXN, FCCN, HYRF, GRXI, UCOI und YHGG! Das sind die Klienten der Javelin Holding, vormals Nicholas Holding und die Vorstände sind auch teils die gleichen. Über deren Betrügereien gibt es gar bei Amazon ein Buch - leider geht das nur bis zur Fusion mit YaSheng!
Antwort auf Beitrag Nr.: 31.428.514 von Charles01 am 07.09.07 03:22:45oh sorry, SIVC habe ich noch vergessen!
Was soll denn da noch laufen? Merger durch! Zonda braucht Geld für Expansion :-) und dann wird's erst mal dauern und der Kurs tief fallen - Short-Betrug! Auf den Aktien-Gewinn würde ich nicht spekulieren! Werte sind bei den Bickels schneller verschwunden, als Du gucken kannst.
Was soll denn da noch laufen? Merger durch! Zonda braucht Geld für Expansion :-) und dann wird's erst mal dauern und der Kurs tief fallen - Short-Betrug! Auf den Aktien-Gewinn würde ich nicht spekulieren! Werte sind bei den Bickels schneller verschwunden, als Du gucken kannst.
Trading Spotlight
Die Millionen, die in solchen Spielchen eingenommen werden, so schätze ich, landen komplett in China und kommen dann als (seriöse) Reverse Merger wieder zurück in die USA. Wie seriös die sind, wird sich im Laufe der Zeit dann zeigen. Es könnte auch dasselbe Spiel mit erheblich höherem Einsatz sein.
Antwort auf Beitrag Nr.: 31.434.809 von Charles01 am 07.09.07 10:22:38Sehr gute Beiträge.
Danke Dir!
Ich persönlich habe von den oben genannten AVWI, CLXN, FCCN und GRXI auf der WL. Der DD für die Dinger brauch recht lange; ich bin immer noch am recherchieren.
Danke Dir!
Ich persönlich habe von den oben genannten AVWI, CLXN, FCCN und GRXI auf der WL. Der DD für die Dinger brauch recht lange; ich bin immer noch am recherchieren.
Hallo
noch sehr ruhig hier
Ich will hier rein
noch sehr ruhig hier
Ich will hier rein
Antwort auf Beitrag Nr.: 31.460.905 von gerdass am 08.09.07 12:02:04follow up eh?
!
Dieser Beitrag wurde moderiert. Grund: Spammposting
News:
CLX Investment Company Gains Majority Ownership of Zonda, Incorporated With Purchase of Additional Equity Interest
2007-10-16 09:38 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 10/16/07
CLX Investment Company, Inc. (OTCBB: CLXN) today announced that it has acquired majority ownership of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets, with the purchase of another 5% of Zonda's issued and outstanding shares. The purchase brings the company's total equity position in Zonda to 51% and paves the way for Zonda to become a major focus of the company's operations.
The additional 5% was acquired from one of Zonda's minority shareholders in exchange for restricted common stock.
Since mid-August 2007, CLX has increased its ownership of Zonda with the acquisition of an additional 15% of Zonda's issued and outstanding shares, raising its equity position from 41% to 51%.
CLX and Zonda have entered into an initial agreement in the form of a letter of intent under which CLX would acquire the remaining issued and outstanding shares of Zonda. Once the remaining due diligence is complete, the companies expect to reach a definitive agreement regarding the acquisition.
Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.
Zonda's intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company's first medical test for Chlamydia is currently sold throughout Europe under the HandiLab brand and is expected to launch in the U.S. at the end of the first quarter 2008. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.
More information regarding Zonda can be found on its official website, www.zondaincusa.com.
"We are pleased to have purchased the additional 5% necessary for CLX to become the majority owner of Zonda," said Steven R. Peacock, consultant CEO of CLX Investment Company. "Zonda is an important cornerstone of our plans to build value for CLX shareholders, and gaining majority control of the company is a critical aspect of this strategy. This purchase triggers several additional events, which we expect to announce in the coming days, that will help to chart the future course of CLX and its plans for Zonda."
CLX Investment Company Gains Majority Ownership of Zonda, Incorporated With Purchase of Additional Equity Interest
2007-10-16 09:38 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 10/16/07
CLX Investment Company, Inc. (OTCBB: CLXN) today announced that it has acquired majority ownership of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for both the medical and non-medical markets, with the purchase of another 5% of Zonda's issued and outstanding shares. The purchase brings the company's total equity position in Zonda to 51% and paves the way for Zonda to become a major focus of the company's operations.
The additional 5% was acquired from one of Zonda's minority shareholders in exchange for restricted common stock.
Since mid-August 2007, CLX has increased its ownership of Zonda with the acquisition of an additional 15% of Zonda's issued and outstanding shares, raising its equity position from 41% to 51%.
CLX and Zonda have entered into an initial agreement in the form of a letter of intent under which CLX would acquire the remaining issued and outstanding shares of Zonda. Once the remaining due diligence is complete, the companies expect to reach a definitive agreement regarding the acquisition.
Zonda's tests utilize proprietary technology that detects enzymes that are specific to the target microorganisms. The Zonda medical diagnostic tests are ideal for the clinical laboratory, point of care, and the over-the-counter (OTC) markets.
Zonda's intellectual property position in enzymatic detection technology will give the company a unique position in the clinical diagnostic market where there is increasing need for simple, reliable, and cost-effective rapid point of care diagnostic tests. The company's first medical test for Chlamydia is currently sold throughout Europe under the HandiLab brand and is expected to launch in the U.S. at the end of the first quarter 2008. Zonda believes it will compete successfully with all current technologies, including the "gold standard" nucleic acid amplification testing (NAAT) technology, while offering several enhanced features.
More information regarding Zonda can be found on its official website, www.zondaincusa.com.
"We are pleased to have purchased the additional 5% necessary for CLX to become the majority owner of Zonda," said Steven R. Peacock, consultant CEO of CLX Investment Company. "Zonda is an important cornerstone of our plans to build value for CLX shareholders, and gaining majority control of the company is a critical aspect of this strategy. This purchase triggers several additional events, which we expect to announce in the coming days, that will help to chart the future course of CLX and its plans for Zonda."
Jetzt hat der Peakock die Mehrheit an Zonda. Mal sehen was er draus macht
So, hier die offizielle Aktion nach den 51%:
Ein 8K
http://knobias.10kwizard.com/filing.php?repo=tenk&ipage=5222…
Ein 8K
http://knobias.10kwizard.com/filing.php?repo=tenk&ipage=5222…
So langsam kommt Leben in die Bude:
CLX Investment Company Announces Agreement With American Health Partners, LLC for Market Readiness and Distribution Management Services
Highlighted Links
CLX Investment Company Website
Zonda, Inc. Website
MURRIETA, CA--(Marketwire - November 13, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced a professional services agreement with American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
With its recent acquisition of a majority percentage of Zonda, CLX's business strategy is focused on the acquisition of innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. Zonda's medical diagnostic tests, which are based upon enzymatic detection technology, are expected to be just one area of focus for CLX, and management is seeking additional innovative products as potential acquisitions. To that end, CEO Vera Leonard has traveled to Dusseldorf, Germany to attend at MEDICA, the world's largest medical trade fair, which is being held from Nov. 14-17.
"AHP has a track record of assisting with the successful launch of new medical diagnostic testing products in the U.S. market, and we are pleased to have entered into this agreement to work with AHP on Zonda's Chlamydia product," stated Ms. Leonard. "As we review additional potential acquisition opportunities for CLX this week at MEDICA, the agreement with AHP takes on even greater significance. We expect that this relationship will be utilized for all future products that are acquired by CLX."
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
About American Health Partners
American Health Partners is known for bringing medical innovations to life through a proprietary MINDMODEL™ process. The AHP market readiness and distribution management system has been utilized to introduce MedMira's Reveal™ G2 Rapid HIV-1 Antibody Test the market's fastest FDA approved HIV test and ThyroTec's ThyroTest™, the first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening device.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. Information regarding Zonda can be found on its official website, www.zondaincusa.com. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Contact:
Gemini Financial Communications
A. Beyer
951-677-8073
Email Contact
CLX Investment Company Announces Agreement With American Health Partners, LLC for Market Readiness and Distribution Management Services
Highlighted Links
CLX Investment Company Website
Zonda, Inc. Website
MURRIETA, CA--(Marketwire - November 13, 2007) - CLX Investment Company, Inc. (OTCBB: CLXN), which owns 51% of Zonda, Incorporated, a developer and manufacturer of unique diagnostic tests for the medical and non-medical markets, today announced a professional services agreement with American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
With its recent acquisition of a majority percentage of Zonda, CLX's business strategy is focused on the acquisition of innovative medical diagnostic technologies that are ideally suited for further development, regulatory approval and distribution in the United States. Zonda's medical diagnostic tests, which are based upon enzymatic detection technology, are expected to be just one area of focus for CLX, and management is seeking additional innovative products as potential acquisitions. To that end, CEO Vera Leonard has traveled to Dusseldorf, Germany to attend at MEDICA, the world's largest medical trade fair, which is being held from Nov. 14-17.
"AHP has a track record of assisting with the successful launch of new medical diagnostic testing products in the U.S. market, and we are pleased to have entered into this agreement to work with AHP on Zonda's Chlamydia product," stated Ms. Leonard. "As we review additional potential acquisition opportunities for CLX this week at MEDICA, the agreement with AHP takes on even greater significance. We expect that this relationship will be utilized for all future products that are acquired by CLX."
To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit http://www.clxinvestments.com/email.php.
About American Health Partners
American Health Partners is known for bringing medical innovations to life through a proprietary MINDMODEL™ process. The AHP market readiness and distribution management system has been utilized to introduce MedMira's Reveal™ G2 Rapid HIV-1 Antibody Test the market's fastest FDA approved HIV test and ThyroTec's ThyroTest™, the first ever FDA approved and CLIA Waived rapid hypothyroid diagnostic screening device.
About CLX Investment Company
CLX Investment Company (www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. Information regarding Zonda can be found on its official website, www.zondaincusa.com. CLX has also invested, and holds a common stock position, in ActionView International, Inc. (www.actionviewinternational.com), a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.
All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.
Contact:
Gemini Financial Communications
A. Beyer
951-677-8073
Email Contact
bewegt sich mal wieder. Scheint die bekomen das FDA aprooval doch langsam auf die Reihe
Antwort auf Beitrag Nr.: 33.730.737 von nellocat am 26.03.08 15:58:42Jep, und gestern ist hat sich das Volumen erneut verzehnfacht. DAs dürfte weiteres MOMO reinbringen.
Bin mal gespannt, ob wir heute die 0.010 knacken. Danach dürfte es dann richtig abgehen!
Bin mal gespannt, ob wir heute die 0.010 knacken. Danach dürfte es dann richtig abgehen!
heute gehts erst mal saftig runter...hab nix gefunden warum und wieso, vleicht weiß ja einer was
GRüße euch Investierte und die es noch werden.
Auf diesem wege präsentiere euch die CLXN, Unsere Perle, die CLXN, die nächste Kurs - Rakete
CLX MEDICAL, INC. OTC BB: CLXN)
CLX MEDICAL, INC. www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc.
CLXN Main Corporate Offices...
29970 Technology Drive
Suite 203
Murrieta, California 92563
Telephone: (951) 677-6735
Fax: (951) 677-6573
Zonda Corporate Office & Mailing Address
Zonda Inc.
17304 Preston Road
Suite 800
Dallas, Texas 75248
Ph: 214 438-3706
Fx: 972 733-6817
Zonda lab:
1781 Vineyard Drive #225
Antioch, Ca. 94509
Ph: (925) 755-0511
Fx: (925) 755-0811
Email:
General Information: info@zondaincusa.com
Sales/Distribution: sales@zondaincusa.com
CLXN Directors/Executive Officers
Vera Leonard 63 President and chief executive Officer
http://www.portfolio.com/resources/executive-profiles/134587…
Robert McCoy 63 DIR
James Bickel 69 DIR
Patrick Edgerton 62 DIR
Transfer Agent
Transfer Online
317 SW Alder St., 2nd Floor
Portland, OR 97204
Phone (503) 227-2950
Fax (503) 227-6874
CLXN Website
http://www.clxinvestments.com/
Authorized Shares: 1,980,000,000 (10-Q/A 12/31/2005)
Outstanding Shares: 470,035,668 (Pinksheets 4/8/2008)
Estimated Market Cap: 658,050 (Pinksheets 4/24/2008)
Shareholders of Record: 582 (Pinksheets 12/31/2007)
Zonda Patent Application
CLX recently announced plans to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials. Concurrently, CLX will be considering additional medical diagnostic products and technologies that may be acquired and/or licensed by CLX.
Investor Relations
Gemini Financial Communications
Email: investors@clxinvestments.com or abeyer@geminicommunications.com
Gemini Financial Communications
Andrew Beyer
951-677-8073
SEC Filings
http://www.secinfo.com/$/SEC/Registrant.asp?CIK=317438'
Other Filings
http://www.sarasotaclerk.com/
Stock Manipulation
http://www.basherbusters.com/information?information_id=534
Zonda, Inc.
CLX also owns a 51% equity interest in Zonda, Inc., a privately held diagnostic testing company that produces diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets.
Zonda distributes its HandiLab products in Europe to both the OTC (over the counter) and POC (point of care) markets. The unique features and advantages of HandiLab have resulted in distribution expansion into most countries of Europe. Zonda is undertaking regulatory approval in the U.S. and Asia, as well as expanding the CE certification it has already earned in Europe. Distribution relationships are being negotiated with many additional companies around the world.
Zonda’s products for the food safety and environmental sanitation markets are unique to Zonda and are not offered or manufactured by any other company. All of Zonda’s food and environmental safety products provide savings in cost and time to these markets. Zonda’s introduction of QuikAlert was in response to the e-coli and Salmonella outbreaks that have affected the food supply over the past several years. QuikAlert is a useful screening tool that can be used to prevent the spread of bacterial food contamination and assure everyone of a safer food supply.
Zonda is expanding into the largest medical sector, the clinical laboratory market, with its introduction of its LabQuik product line. The LabQuik product line of culture confirmation spot tests, stains and reagents are offered at very competitive prices
http://www.zondaincusa.com/index.php'
QuickAlert Video (e-coli test product):
http://www.zondaincusa.com/index2.php?id=video
NEW! HandiLab Testing Device Video:http://www.zondaincusa.com/videos/HL-Procedure/HandiLab.html
State of Incorporation: Nevada
Corporate Address:
PO Box 475
Rio Vista, CA 94571
Telephone 925-755-0511
Fax 925-755-0811
Zonda - Management
Patrick L. Edgerton - Chairman, Vice President of U.S. and European Distribution
Vera Leonard - President/CEO
Pavel Holik - Director of Commercial Operations
Ms. Leonard has considerable successful experience in leadership positions with major medical manufacturing and distribution companies. From 1999 to 2003 Ms. Leonard served as vice president of U.S. sales for Quidel Corporation, a Nasdaq listed company that specializes in rapid, point-of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately $8 million in annual revenue and helped to grow revenues from $32 million to $51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than $1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees. Under Ms. Leonard's leadership, the company received awards for outstanding sales performance and distribution partnering from industry-leading distributors 3 years in a row and 4 years total. She restructured the sales and support organization to establish standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership. From 2004 to 2005 Ms. Leonard served as director of vendor relations for Henry Schein, Inc., a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability. From 2005 to 2007 Ms. Leonard served as President of Vera Leonard, Inc., an alliance that provides business consulting, leadership development, sales training and executive coaching to individuals and corporations. Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms.
Clinical Sample Storage
In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics.
Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities.
In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging.
For additional details regarding Sentry's capabilities and services, please visit http://www.sentrylogistic.com/services.php.
Vaildation Studies
IIT Research Institute (IITRI) (http://www.iitri.org) will serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia.
A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.
IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.
IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility.
Clinical Trials
American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (http://www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
Safis Solutions (http://www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.
Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.
Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.
TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.
4/30/08 LOI for FDA approved CLIA waived test kit
CLXN announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.
The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.
2008 UPDATED PRODUCT LAUNCHES!!!!
Chlamydia: - Clinical trials underway for FDA clearance. Targeted to Launch at the end of Q2 2008
Gonorrhea: - Targeted to Launch Q3 2008
Strep-A: - Targeted to Launch Q3 2008
Yeast: - Targeted to Launch Q3 2008
Get the latest NEWS Releases:
http://finance.yahoo.com/q?s=CLXN.OB
FACTS ABOUT HandiLab
*Rapid
*Self-Contained
*Point of Care and OTC (self testing)
...... Dianostic System
Core technology
Proprietary enzyme detection system (patent pending) consisting of a synthetic substrate which, in the presence of an enzyme specific to the infectious disease, causes a chemical reaction.
This reaction, when coupled to a developing agent, causes a color to appear on the tip of the swab.
Competing Technologies to HandiLab
*Culture
*Nucleic Acid Probe
*Antigen Detection
*Polymerase Chain Reaction (PCR)
Advantages of HandiLab
*NOequipment needed
*NOexpensive instrumentation necessary
*NOadditional reagents to store
*NOoff-line extraction; self-contained
*NOexpensive employee training
*3easy steps
*FASTresults at point-of-care
*DIAGNOSEand treat patients in same visit
Customers for HandiLab
Point of Care - Doctors Offices
Laboratories
Public health/STD Clinics
University Health Clinics
Over The Counter (OTC) Pharmacies
What does CLIA waived mean?
http://www.fda.gov/cdrh/clia/cliawaived.html
A list of CLIA waived tests since 2000:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/tes…
Get the Latest SEC info:
http://finance.yahoo.com/q/sec?s=CLXN.OB
Get the Latest Company Events:
http://finance.yahoo.com/q/ce?s=CLXN.OB
Auf diesem wege präsentiere euch die CLXN, Unsere Perle, die CLXN, die nächste Kurs - Rakete
CLX MEDICAL, INC. OTC BB: CLXN)
CLX MEDICAL, INC. www.clxinvestments.com) holds a 51% equity interest in Zonda, Inc. CLX has also invested, and holds a common stock position, in ActionView International, Inc.
CLXN Main Corporate Offices...
29970 Technology Drive
Suite 203
Murrieta, California 92563
Telephone: (951) 677-6735
Fax: (951) 677-6573
Zonda Corporate Office & Mailing Address
Zonda Inc.
17304 Preston Road
Suite 800
Dallas, Texas 75248
Ph: 214 438-3706
Fx: 972 733-6817
Zonda lab:
1781 Vineyard Drive #225
Antioch, Ca. 94509
Ph: (925) 755-0511
Fx: (925) 755-0811
Email:
General Information: info@zondaincusa.com
Sales/Distribution: sales@zondaincusa.com
CLXN Directors/Executive Officers
Vera Leonard 63 President and chief executive Officer
http://www.portfolio.com/resources/executive-profiles/134587…
Robert McCoy 63 DIR
James Bickel 69 DIR
Patrick Edgerton 62 DIR
Transfer Agent
Transfer Online
317 SW Alder St., 2nd Floor
Portland, OR 97204
Phone (503) 227-2950
Fax (503) 227-6874
CLXN Website
http://www.clxinvestments.com/
Authorized Shares: 1,980,000,000 (10-Q/A 12/31/2005)
Outstanding Shares: 470,035,668 (Pinksheets 4/8/2008)
Estimated Market Cap: 658,050 (Pinksheets 4/24/2008)
Shareholders of Record: 582 (Pinksheets 12/31/2007)
Zonda Patent Application
CLX recently announced plans to initiate clinical trials for Zonda's rapid point of care test for Chlamydia as part of the process to achieve FDA clearance for the product. CLX anticipates a mid to late first calendar quarter 2008 beginning for the clinical trials. Concurrently, CLX will be considering additional medical diagnostic products and technologies that may be acquired and/or licensed by CLX.
Investor Relations
Gemini Financial Communications
Email: investors@clxinvestments.com or abeyer@geminicommunications.com
Gemini Financial Communications
Andrew Beyer
951-677-8073
SEC Filings
http://www.secinfo.com/$/SEC/Registrant.asp?CIK=317438'
Other Filings
http://www.sarasotaclerk.com/
Stock Manipulation
http://www.basherbusters.com/information?information_id=534
Zonda, Inc.
CLX also owns a 51% equity interest in Zonda, Inc., a privately held diagnostic testing company that produces diagnostic tests that serve the medical, bacterial food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets.
Zonda distributes its HandiLab products in Europe to both the OTC (over the counter) and POC (point of care) markets. The unique features and advantages of HandiLab have resulted in distribution expansion into most countries of Europe. Zonda is undertaking regulatory approval in the U.S. and Asia, as well as expanding the CE certification it has already earned in Europe. Distribution relationships are being negotiated with many additional companies around the world.
Zonda’s products for the food safety and environmental sanitation markets are unique to Zonda and are not offered or manufactured by any other company. All of Zonda’s food and environmental safety products provide savings in cost and time to these markets. Zonda’s introduction of QuikAlert was in response to the e-coli and Salmonella outbreaks that have affected the food supply over the past several years. QuikAlert is a useful screening tool that can be used to prevent the spread of bacterial food contamination and assure everyone of a safer food supply.
Zonda is expanding into the largest medical sector, the clinical laboratory market, with its introduction of its LabQuik product line. The LabQuik product line of culture confirmation spot tests, stains and reagents are offered at very competitive prices
http://www.zondaincusa.com/index.php'
QuickAlert Video (e-coli test product):
http://www.zondaincusa.com/index2.php?id=video
NEW! HandiLab Testing Device Video:http://www.zondaincusa.com/videos/HL-Procedure/HandiLab.html
State of Incorporation: Nevada
Corporate Address:
PO Box 475
Rio Vista, CA 94571
Telephone 925-755-0511
Fax 925-755-0811
Zonda - Management
Patrick L. Edgerton - Chairman, Vice President of U.S. and European Distribution
Vera Leonard - President/CEO
Pavel Holik - Director of Commercial Operations
Ms. Leonard has considerable successful experience in leadership positions with major medical manufacturing and distribution companies. From 1999 to 2003 Ms. Leonard served as vice president of U.S. sales for Quidel Corporation, a Nasdaq listed company that specializes in rapid, point-of care diagnostic tests, Ms. Leonard led negotiations on agreements that added approximately $8 million in annual revenue and helped to grow revenues from $32 million to $51 million in 3 years. She delivered an unprecedented 6 consecutive quarters of financial performance that met or exceeded expectations and saved more than $1,500,000 annually for the company from renegotiations of growth incentive plan, implementation of net pricing strategy and elimination of GPO administration fees. Under Ms. Leonard's leadership, the company received awards for outstanding sales performance and distribution partnering from industry-leading distributors 3 years in a row and 4 years total. She restructured the sales and support organization to establish standards of performance, goal-driven compensation plan, territory-level budget and forecast management while developing individuals for promotion to levels of greater responsibility and leadership. From 2004 to 2005 Ms. Leonard served as director of vendor relations for Henry Schein, Inc., a Fortune 500 distributor of medical and dental supplies to office-based practices worldwide. In this position, she launched 6 new products; negotiated semi-exclusive distribution rights on three innovative new products; designed a product launch template that was adopted for standard use by the entire medical marketing team; negotiated an exclusive special pricing agreement on market-leading product to maximize competitive conversions; and completed an in-depth pricing analysis by vendor, sales division and SKU to assess pricing strategies and assure competitive positioning while maximizing profitability. From 2005 to 2007 Ms. Leonard served as President of Vera Leonard, Inc., an alliance that provides business consulting, leadership development, sales training and executive coaching to individuals and corporations. Previous to these positions, Ms. Leonard served as sales representative, sales manager, regional sales manager, and national sales manager for medical manufacturing and distribution companies where she developed an extensive firsthand knowledge of the medical supply field. These companies ranged from start-ups to major U.S. and international firms.
Clinical Sample Storage
In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics.
Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities.
In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging.
For additional details regarding Sentry's capabilities and services, please visit http://www.sentrylogistic.com/services.php.
Vaildation Studies
IIT Research Institute (IITRI) (http://www.iitri.org) will serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia.
A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.
IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.
IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility.
Clinical Trials
American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (http://www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
Safis Solutions (http://www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.
Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.
Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.
TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.
4/30/08 LOI for FDA approved CLIA waived test kit
CLXN announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.
The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.
2008 UPDATED PRODUCT LAUNCHES!!!! Chlamydia: - Clinical trials underway for FDA clearance. Targeted to Launch at the end of Q2 2008
Gonorrhea: - Targeted to Launch Q3 2008
Strep-A: - Targeted to Launch Q3 2008
Yeast: - Targeted to Launch Q3 2008
Get the latest NEWS Releases:
http://finance.yahoo.com/q?s=CLXN.OB
FACTS ABOUT HandiLab
*Rapid
*Self-Contained
*Point of Care and OTC (self testing)
...... Dianostic System
Core technology
Proprietary enzyme detection system (patent pending) consisting of a synthetic substrate which, in the presence of an enzyme specific to the infectious disease, causes a chemical reaction.
This reaction, when coupled to a developing agent, causes a color to appear on the tip of the swab.
Competing Technologies to HandiLab
*Culture
*Nucleic Acid Probe
*Antigen Detection
*Polymerase Chain Reaction (PCR)
Advantages of HandiLab
*NOequipment needed
*NOexpensive instrumentation necessary
*NOadditional reagents to store
*NOoff-line extraction; self-contained
*NOexpensive employee training
*3easy steps
*FASTresults at point-of-care
*DIAGNOSEand treat patients in same visit
Customers for HandiLab
Point of Care - Doctors Offices
Laboratories
Public health/STD Clinics
University Health Clinics
Over The Counter (OTC) Pharmacies
What does CLIA waived mean?
http://www.fda.gov/cdrh/clia/cliawaived.html
A list of CLIA waived tests since 2000:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/tes…
Get the Latest SEC info:
http://finance.yahoo.com/q/sec?s=CLXN.OB
Get the Latest Company Events:
http://finance.yahoo.com/q/ce?s=CLXN.OB
http://www.zondaincusa.com/documents/Hungarian%20PCR-HandiLa…
http://www.zondaincusa.com/documents/Poster_Session.pdf
http://www.unicorp.hu/docs/b_handylab_uk.pdf
http://investorshub.advfn.com/boards/read_msg.asp?message_id…
Posted by: ThePennyGuru
For the newbies- Here is what is going on with CLXN:
1. An LOI for a FDA approved CLIA waived Rapid test kit is expected anytime. CLIA waived means it can be done in a Doctor's office and does not have to be sent to a lab. They will have a product that can produce alot of revenues immediately.
2. Validation Studies are underway. Basically, a culture of Clamidia is grown in the lab. They then test to see if the chemical agent of the test kit reacts to the culture. Proof the science works. This is more a formality as the test works. Once this is done the product can be sold in Europe, S. America and most of Asia as they do not require FDA approval. Once the culture is grown, the testing takes 2-3 days. The validation studies are used to train the lab people on the protocols that will be used in the clinical trials. This will be completed by the end of May.
3. Announcement of the European Distributor- I believe this company will handle the rest of the world also.
4. Once Validation studies are done, they will move on to the clinicals. This is a test kit so the clinicals are very simplistic. They need to test a certain number of patients to see if it works 400-600. The clinicals will take less than 2 weeks. I am looking for FDA approval by end of Summer to early fall. Then they will have the product China FDA approved.
5. Once the Clamidia test kit has FDA approval, they will move on to Gonorrhea. This test kit will be bigger than the Clamidia test kit.
http://www.zondaincusa.com/documents/Poster_Session.pdf
http://www.unicorp.hu/docs/b_handylab_uk.pdf
http://investorshub.advfn.com/boards/read_msg.asp?message_id…
Posted by: ThePennyGuru
For the newbies- Here is what is going on with CLXN:
1. An LOI for a FDA approved CLIA waived Rapid test kit is expected anytime. CLIA waived means it can be done in a Doctor's office and does not have to be sent to a lab. They will have a product that can produce alot of revenues immediately.
2. Validation Studies are underway. Basically, a culture of Clamidia is grown in the lab. They then test to see if the chemical agent of the test kit reacts to the culture. Proof the science works. This is more a formality as the test works. Once this is done the product can be sold in Europe, S. America and most of Asia as they do not require FDA approval. Once the culture is grown, the testing takes 2-3 days. The validation studies are used to train the lab people on the protocols that will be used in the clinical trials. This will be completed by the end of May.
3. Announcement of the European Distributor- I believe this company will handle the rest of the world also.
4. Once Validation studies are done, they will move on to the clinicals. This is a test kit so the clinicals are very simplistic. They need to test a certain number of patients to see if it works 400-600. The clinicals will take less than 2 weeks. I am looking for FDA approval by end of Summer to early fall. Then they will have the product China FDA approved.
5. Once the Clamidia test kit has FDA approval, they will move on to Gonorrhea. This test kit will be bigger than the Clamidia test kit.
CLX Medical, Inc. Announces Form 4 Filings by Board of Directors
Monday September 15, 1:39 pm ET
MURRIETA, CA--(MARKET WIRE)--Sep 15, 2008 -- CLX Medical, Inc. (OTC BB:CLXN.OB - News), which is focused on the launch and distribution of unique medical diagnostic testing products, today announced Form 4 filings by the company's Board of Directors.
On September 12, 2008, Directors Robert McCoy, Patrick Edgerton and James Bickel each filed a Form 4 Statement of Change in Beneficial Ownership of Securities with the Securities and Exchange Commission. The stock acquired by each of the Directors was granted by the company dating back as far as January 2007 as part of their respective compensation packages.
http://biz.yahoo.com/iw/080915/0433840.html
34,362,031 shares of CLXN for a job well done.
CLX Medical, Inc. Announces a Definitive Agreement for the Acquisition of the ThyroTest(R) Rapid Screening Device
2008-09-16 09:42 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 09/16/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, today announced that the company has executed a definitive agreement to acquire ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.
ThyroTest® is FDA cleared and has also achieved CLIA waived status, so the test can be administered in the more than 100,000 CLIA waived doctors' offices in the U.S., as well as in any non-waived laboratory.
A Current Report on Form 8-K regarding the Definitive Agreement is expected to be filed with the Securities and Exchange Commission later today.
The definitive agreement was signed with ThyroTec, LLC, the developer of the ThyroTest® device. ThyroTec develops and markets medical diagnostic devices and products for use and application in the medical services industry.
http://investorshub.advfn.com/boards/board.aspx?board_id=434…
CLX Medical, Inc. Files Form 8-K on Definitive Agreement for the Acquisition of the ThyroTest(R) Rapid Screening Device
2008-09-17 10:02 ET - News Release
MURRIETA, CA -- (MARKET WIRE) -- 09/17/08
CLX Medical, Inc. (OTCBB: CLXN), which is focused on the marketing and distribution of unique medical diagnostic testing products, has filed a Current Report on Form 8-K regarding its planned purchase of ThyroTest®, a rapid thyroid stimulating hormone (TSH) screening device used for the detection of hypothyroidism in adults, a common thyroid disease.
The Form 8-K can be accessed through a link to SEC filings in the "Corporate" section of the CLX Medical website, www.clxmedical.com.
The Form 8-K reports that on September 9, 2008, CLX Medical entered into a product purchase agreement with ThyroTec, LLC, the developer of the ThyroTest® device, pursuant to which CLX Medical will acquire from ThryoTec the exclusive, worldwide rights to ThyroTest®, together with related packaging and marketing materials. The purchase price for the acquisition consists of a cash payment of $750,000 upon closing and the issuance of Series C convertible preferred stock of CLX Medical convertible into fifteen percent (15%) of the total, fully-diluted common stock of the company.
Upon closing, Jim Small, ThyroTec's chief executive officer, or his designate will be appointed as a member of CLX Medical's board of directors. Mr. Small has 30 years of thyroid related pharmaceutical experience and is the co-founder of ThyroTec. A detailed biography of Mr. Small will
http://investorshub.advfn.com/boards/board.aspx?board_id=434…
CLXN Website
http://www.clxinvestments.com/" target="_blank" rel="nofollow ugc noopener">http://www.clxinvestments.com/
Weitere Info findet Ihr u.a. bei dem Amerikanishen Board Investorshub, Viele kennen unter IHUB:
http://investorshub.advfn.com/boards/board.aspx?board_id=338…
http://www.clxinvestments.com/" target="_blank" rel="nofollow ugc noopener">http://www.clxinvestments.com/
Weitere Info findet Ihr u.a. bei dem Amerikanishen Board Investorshub, Viele kennen unter IHUB:
http://investorshub.advfn.com/boards/board.aspx?board_id=338…
Jetzt einsteigen und einer der esten sein
CLXN - Noch ziehmlich unentdeckt, eine wahre Perle
PS: The Sky is The Limit
CLXN - Strong Buy and Stay Long $$$$
Gruß Euer Tomcat14
Gruß Euer Tomcat14
TomCat14 ist seit einem Tag registriert!!! Na dann viel Spaß beim weiterbashen!
Wie baschen, Was ist denn los?.Ich zum Beispiel bin seit über 20 Jahren, seit über 20 Jahren Trade ich an der NYSE, und bin heute registriert, Die Dauer der Regustrierdatum hat definitiv nichts ,mit der Erfahrung von Aktien zu tun,
Nun, Wir wollen ja nicht über investierte User reden, Ich werde Mir gleich welche von CLXN kaufen , Da ist was im Busch Leute, Das riecht nach Geld
, Bis gleich
Nun, Wir wollen ja nicht über investierte User reden, Ich werde Mir gleich welche von CLXN kaufen , Da ist was im Busch Leute, Das riecht nach Geld
, Bis gleich
So, Hab mir mal eben 10.000.000 Stück von CLXN gegönnt, werde natürlich nachkaufen, da ist was im Busch,Da bahnt sich was großes an
Sag mal Leute die Quartakszahlen sollen doch am 3.,09 kommen,oder Weißt jemand wann die kommen?
Hier ist der Richtige Link; http://www.clxmedical.com/
Sowas kommt nur einmal im Leben, Leute, Kaufen und liegenlassen, Ich verkaufe keine unter 1 euro
USGenera
USGenera
Antwort auf Beitrag Nr.: 35.175.877 von UsGenera1 am 18.09.08 21:30:12nicht mit mir
Leute da bahnt sich was an, würde nicht wundern, wen das in absehbarer Zeit um 1000-10000+% Prozente hochscießt
Ich werde morgen noch paar Millionen nachkaufen
CLXN - Strong Buy and Stay Long $$$$
Giten Morgen, Ich habe hier einige Daten für euch zusammengestellt, ist sehr interessant:
http://www.zondaincusa.com/documents/Hungarian%20PCR-HandiLa…
http://www.zondaincusa.com/documents/Poster_Session.pdf
http://www.unicorp.hu/docs/b_handylab_uk.pdf
http://investorshub.advfn.com/boards/read_msg.asp?message_id…
Posted by: ThePennyGuru
For the newbies- Here is what is going on with CLXN:
1. An LOI for a FDA approved CLIA waived Rapid test kit is expected anytime. CLIA waived means it can be done in a Doctor's office and does not have to be sent to a lab. They will have a product that can produce alot of revenues immediately.
2. Validation Studies are underway. Basically, a culture of Clamidia is grown in the lab. They then test to see if the chemical agent of the test kit reacts to the culture. Proof the science works. This is more a formality as the test works. Once this is done the product can be sold in Europe, S. America and most of Asia as they do not require FDA approval. Once the culture is grown, the testing takes 2-3 days. The validation studies are used to train the lab people on the protocols that will be used in the clinical trials. This will be completed by the end of May.
3. Announcement of the European Distributor- I believe this company will handle the rest of the world also.
4. Once Validation studies are done, they will move on to the clinicals. This is a test kit so the clinicals are very simplistic. They need to test a certain number of patients to see if it works 400-600. The clinicals will take less than 2 weeks. I am looking for FDA approval by end of Summer to early fall. Then they will have the product China FDA approved.
5. Once the Clamidia test kit has FDA approval, they will move on to Gonorrhea. This test kit will be bigger than the Clamidia test kit.
Advantages of HandiLab
*NOequipment needed
*NOexpensive instrumentation necessary
*NOadditional reagents to store
*NOoff-line extraction; self-contained
*NOexpensive employee training
*3easy steps
*FASTresults at point-of-care
*DIAGNOSEand treat patients in same visit
Customers for HandiLab
Point of Care - Doctors Offices
Laboratories
Public health/STD Clinics
University Health Clinics
Over The Counter (OTC) Pharmacies
What does CLIA waived mean?
http://www.fda.gov/cdrh/clia/cliawaived.html
A list of CLIA waived tests since 2000:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/tes…
FACTS ABOUT HandiLab
*Rapid
*Self-Contained
*Point of Care and OTC (self testing)
...... Dianostic System
Core technology
Proprietary enzyme detection system (patent pending) consisting of a synthetic substrate which, in the presence of an enzyme specific to the infectious disease, causes a chemical reaction.
This reaction, when coupled to a developing agent, causes a color to appear on the tip of the swab.
Competing Technologies to HandiLab
*Culture
*Nucleic Acid Probe
*Antigen Detection
*Polymerase Chain Reaction (PCR)
4/30/08 LOI for FDA approved CLIA waived test kit
CLXN announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.
The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.
2008 UPDATED PRODUCT LAUNCHES!!!!
Chlamydia: - Clinical trials underway for FDA clearance. Targeted to Launch at the end of Q2 2008
Gonorrhea: - Targeted to Launch Q3 2008
Strep-A: - Targeted to Launch Q3 2008
Yeast: - Targeted to Launch Q3 2008
Get the latest NEWS Releases:
http://finance.yahoo.com/q?s=CLXN.OB
Get the Latest SEC info:
http://finance.yahoo.com/q/sec?s=CLXN.OB
Get the Latest Company Events:
http://finance.yahoo.com/q/ce?s=CLXN.OB
Clinical Sample Storage
In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics.
Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities.
In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging.
For additional details regarding Sentry's capabilities and services, please visit http://www.sentrylogistic.com/services.php.
Vaildation Studies
IIT Research Institute (IITRI) (http://www.iitri.org) will serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia.
A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.
IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.
IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility.
Clinical Trials
American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (http://www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
Safis Solutions (http://www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.
Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.
Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.
TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.
http://www.zondaincusa.com/documents/Hungarian%20PCR-HandiLa…
http://www.zondaincusa.com/documents/Poster_Session.pdf
http://www.unicorp.hu/docs/b_handylab_uk.pdf
http://investorshub.advfn.com/boards/read_msg.asp?message_id…
Posted by: ThePennyGuru
For the newbies- Here is what is going on with CLXN:
1. An LOI for a FDA approved CLIA waived Rapid test kit is expected anytime. CLIA waived means it can be done in a Doctor's office and does not have to be sent to a lab. They will have a product that can produce alot of revenues immediately.
2. Validation Studies are underway. Basically, a culture of Clamidia is grown in the lab. They then test to see if the chemical agent of the test kit reacts to the culture. Proof the science works. This is more a formality as the test works. Once this is done the product can be sold in Europe, S. America and most of Asia as they do not require FDA approval. Once the culture is grown, the testing takes 2-3 days. The validation studies are used to train the lab people on the protocols that will be used in the clinical trials. This will be completed by the end of May.
3. Announcement of the European Distributor- I believe this company will handle the rest of the world also.
4. Once Validation studies are done, they will move on to the clinicals. This is a test kit so the clinicals are very simplistic. They need to test a certain number of patients to see if it works 400-600. The clinicals will take less than 2 weeks. I am looking for FDA approval by end of Summer to early fall. Then they will have the product China FDA approved.
5. Once the Clamidia test kit has FDA approval, they will move on to Gonorrhea. This test kit will be bigger than the Clamidia test kit.
Advantages of HandiLab
*NOequipment needed
*NOexpensive instrumentation necessary
*NOadditional reagents to store
*NOoff-line extraction; self-contained
*NOexpensive employee training
*3easy steps
*FASTresults at point-of-care
*DIAGNOSEand treat patients in same visit
Customers for HandiLab
Point of Care - Doctors Offices
Laboratories
Public health/STD Clinics
University Health Clinics
Over The Counter (OTC) Pharmacies
What does CLIA waived mean?
http://www.fda.gov/cdrh/clia/cliawaived.html
A list of CLIA waived tests since 2000:
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfClia/tes…
FACTS ABOUT HandiLab
*Rapid
*Self-Contained
*Point of Care and OTC (self testing)
...... Dianostic System
Core technology
Proprietary enzyme detection system (patent pending) consisting of a synthetic substrate which, in the presence of an enzyme specific to the infectious disease, causes a chemical reaction.
This reaction, when coupled to a developing agent, causes a color to appear on the tip of the swab.
Competing Technologies to HandiLab
*Culture
*Nucleic Acid Probe
*Antigen Detection
*Polymerase Chain Reaction (PCR)
4/30/08 LOI for FDA approved CLIA waived test kit
CLXN announced that after a period of initial due diligence and negotiations, the company has progressed to a letter of intent to acquire a rapid diagnostic device for the medical market.
The due diligence process will continue as CLX pursues a definitive agreement and the close of the acquisition of the device. Once CLX has reached a mutually agreed upon point in its due diligence process, it will announce the name of the device and the market that it serves.
The acquisition target presents considerable synergies with the product line of Zonda, Incorporated, a majority owned subsidiary of CLX that has developed a rapid point of care test for chlamydia. CLX is currently preparing to initiate clinical trials for the Zonda chlamydia test as part of the effort to achieve FDA clearance for the product. The company recently announced a validation study to perfect the testing protocol in preparation for the clinical trials.
2008 UPDATED PRODUCT LAUNCHES!!!! Chlamydia: - Clinical trials underway for FDA clearance. Targeted to Launch at the end of Q2 2008
Gonorrhea: - Targeted to Launch Q3 2008
Strep-A: - Targeted to Launch Q3 2008
Yeast: - Targeted to Launch Q3 2008
Get the latest NEWS Releases:
http://finance.yahoo.com/q?s=CLXN.OB
Get the Latest SEC info:
http://finance.yahoo.com/q/sec?s=CLXN.OB
Get the Latest Company Events:
http://finance.yahoo.com/q/ce?s=CLXN.OB
Clinical Sample Storage
In preparation for planned clinical trials for Zonda's rapid point of care test for Chlamydia, the tests that will be used in the trials have been placed in an FDA compliant, GMP approved secure storage facility provided by Sentry Logistic Solutions ("Sentry"), a leading provider of temperature-controlled storage and third party logistics.
Sentry offers refrigerated, ambient, frozen and ultra low storage, logistics and distribution services for a broad range of clinical and commercial biopharmaceutical materials and components. Its experienced staff and 53,000 square-foot facility can handle virtually any storage need and enhance a client's supply chain capabilities.
In anticipation of the initiation of clinical trials scheduled for the mid- to late-1st calendar quarter of 2008, Sentry has received a sufficient supply of Chlamydia tests in bulk and will disseminate them for use in the trials as appropriate. Sentry will also provide additional services related to the storage and distribution of the tests including cold chain logistics, labeling and packaging.
For additional details regarding Sentry's capabilities and services, please visit http://www.sentrylogistic.com/services.php.
Vaildation Studies
IIT Research Institute (IITRI) (http://www.iitri.org) will serve as the laboratory that will conduct a validation study for Zonda's rapid point of care test for chlamydia.
A major purpose of the validation study is to perfect the testing protocol in preparation for the clinical trials as part of the process to achieve FDA clearance for the product.
IIT Research Institute has provided non-clinical research and development services to the U.S. government and to sponsors in the pharmaceutical, biotechnology, chemical, agrichemical, and personal products industries for more than 40 years. IITRI scientists work closely with its sponsors to plan and implement programs in drug discovery, efficacy evaluation, and non-clinical development. Data from GLP-compliant programs conducted at IITRI are commonly used to support Investigational New Drug applications (INDs), New Drug Applications (NDAs), and other submissions to regulatory agencies around the world.
IITRI operates more than 125,000 square feet of state-of-the-art laboratory and support space in its Chicago facility.
Clinical Trials
American Health Partners, LLC (AHP), under which AHP will assist with the launch of medical diagnostic testing in CLX subsidiary operations. The first product for which CLX is expected to utilize AHP's market readiness process and distribution management system is Zonda's rapid point of care test for Chlamydia.
The professional services agreement outlines the services that AHP is expected to provide, including preliminary market validation for product efficacy, establishment of clinical trials protocol to meet the appropriate regulatory requirements, completion of clinical trials, assistance with targeted regulatory approvals for distribution of products within the United States, a market readiness audit, a manufacturing plan, a marketing plan, and a distribution plan to include the identification of and a contract with "1st Choice" distributors.
AHP (http://www.ahpartners.com) has over 30 years of experience in the marketing and distribution of professional medical products and has experience in preparing products for market launch in the United States.
Safis Solutions (http://www.safis-solutions.com), an Indianapolis-based regulatory compliance consulting company serving pharmaceutical, medical device and biotech companies worldwide, has been retained as a sub-contractor of American Health Partners, LLC (AHP), which has been engaged by CLX to assist with the launch of medical diagnostic testing products in its subsidiary operations. Safis Solutions is providing ongoing consulting services in the areas of regulatory approvals and quality systems for Zonda and additional potential future medical diagnostic technologies acquired by CLX.
Contract Research Organization (CRO) for the clinical trials for Zonda's rapid point of care test for chlamydia.
Trial Care International, LLC (http://trialcareintl.com/index.html) specializes in the management of Phase I-IV clinical trials in a wide range of therapeutic areas and provides clinical management, monitoring, auditing and regulatory services to the pharmaceutical and biotech industry through partnering and long-term relationships with its clients.
TCI offers a full range of clinical services specializing in: protocol design, project management, investigator recruitment and selection, document collection and supply shipping, contract and grant administration, investigator meeting coordination and facilitation, monitoring, GCP auditing and regulatory consulting.
Handelst sich wohl um das neue patentierte Produckt von CLXN, was demnächst auf den Markt kommt
So wie Ich geört habe, wachen auch langsam die Amis auf
Ich werde heute nochmal ne fette Kauforder reinstellen, wenn nellocat dabei ist, wird es sich sehr um eine sehr sehr aussichtreiche Aktie zu habdeln.
Leute früh einsteigen und einfach liegenlassen, wird demnächst hochschießen, oder positioniert euch schonmal
Leute früh einsteigen und einfach liegenlassen, wird demnächst hochschießen, oder positioniert euch schonmal
CLXN - Strong Buy, wahre Perle. nd nichtn unter einem 1 US$ verkaufen, ZUmindet Ich vge keine Stücke unter 1 US$ her, im Gegenteil, Ich werde bei diesen Preisen nachkaufen.Wahre Kusrakete, Wird demnächst durch die Decke katapultiert werden $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$
CLXN - Strong Buy
Gruß Eure Susann112
, im Gegenteil, Ich werde bei diesen Preisen nachkaufen.Wahre Kusrakete, Wird demnächst durch die Decke katapultiert werden $$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$$CLXN - Strong Buy
Gruß Eure Susann112
<div style="border: 1px solid #000;"
Diesen Threaad schließen wir.
Bei weiterem Diskussionsbedarf bitte BM an mich.
MfG MaatMOD</div>
Diesen Threaad schließen wir.
Bei weiterem Diskussionsbedarf bitte BM an mich.
MfG MaatMOD</div>
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 151 | ||
| 90 | ||
| 74 | ||
| 68 | ||
| 52 | ||
| 45 | ||
| 39 | ||
| 38 | ||
| 38 | ||
| 31 |
| Wertpapier | Beiträge | |
|---|---|---|
| 24 | ||
| 24 | ||
| 22 | ||
| 19 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 |
